Logo image of TVRD

TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

NASDAQ:TVRD - Nasdaq - US1407553072 - Common Stock - Currency: USD

24.75  +0.41 (+1.68%)

Fundamental Rating

2

TVRD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. The financial health of TVRD is average, but there are quite some concerns on its profitability. TVRD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TVRD had negative earnings in the past year.
TVRD had a negative operating cash flow in the past year.
TVRD had negative earnings in 4 of the past 5 years.
TVRD had a negative operating cash flow in each of the past 5 years.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

TVRD has a worse Return On Assets (-115.70%) than 77.95% of its industry peers.
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 86.08%, TVRD belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
TVRD has more shares outstanding than it did 1 year ago.
TVRD has less shares outstanding than it did 5 years ago.
TVRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -25.46, we must say that TVRD is in the distress zone and has some risk of bankruptcy.
TVRD's Altman-Z score of -25.46 is on the low side compared to the rest of the industry. TVRD is outperformed by 83.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.46
ROIC/WACCN/A
WACC10%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 32.48 indicates that TVRD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 32.48, TVRD belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
TVRD has a Quick Ratio of 31.73. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TVRD (31.73) is better than 98.46% of its industry peers.
Industry RankSector Rank
Current Ratio 32.48
Quick Ratio 31.73
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.65% over the past year.
Looking at the last year, TVRD shows a very negative growth in Revenue. The Revenue has decreased by -55.30% in the last year.
Measured over the past years, TVRD shows a very negative growth in Revenue. The Revenue has been decreasing by -18.54% on average per year.
EPS 1Y (TTM)30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
Revenue 1Y (TTM)-55.3%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%20.33%

3.2 Future

TVRD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.78% yearly.
TVRD is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y16.62%
EPS Next 2Y15.66%
EPS Next 3Y7.78%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.
Also next year TVRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.66%
EPS Next 3Y7.78%

More info and screens

0

5. Dividend

5.1 Amount

TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (6/5/2025, 2:14:45 PM)

24.75

+0.41 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners24.64%
Inst Owner ChangeN/A
Ins Owners0.87%
Ins Owner Change100%
Market Cap231.66M
Analysts82.5
Price Target40.02 (61.7%)
Short Float %0.96%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)49.63%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)109.89%
Revenue beat(4)2
Avg Revenue beat(4)34.26%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)109.89%
Revenue beat(8)4
Avg Revenue beat(8)5.44%
Revenue beat(12)7
Avg Revenue beat(12)0.17%
Revenue beat(16)9
Avg Revenue beat(16)-1.11%
PT rev (1m)6.86%
PT rev (3m)N/A
EPS NQ rev (1m)-214.29%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-38.96%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.6
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-29.6
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-3.83
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS0.81
BVpS-0.86
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.08%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.48
Quick Ratio 31.73
Altman-Z -25.46
F-Score6
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
EPS Next Y16.62%
EPS Next 2Y15.66%
EPS Next 3Y7.78%
EPS Next 5YN/A
Revenue 1Y (TTM)-55.3%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%20.33%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y76.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5YN/A
FCF growth 1Y59.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.45%
OCF growth 3YN/A
OCF growth 5YN/A